Ibrutinib + Venetoclax Extends PFS in Advanced Mantle Cell… : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
The FDA granted priority review to an sBLA seeking the approval of pembrolizumab plus chemotherapy as frontline therapy in malignant pleural mesothelioma.
A ground breaking staging system for de novo metastatic breast cancer has been validated in an international cohort, perhaps paving the way for more personalized…
The XIX International Symposium on Amyloidosis (ISA) will be held in Rochester, MN, between May 26-30, 2024. This meeting will cover a variety of amyloidosis…
and Infants Network) conducted enhanced surveillance among people with syphilis during pregnancy based on case investigations, medical records, and linkage of laboratory data with vital…
The European Commission approved nivolumab plus cisplatin and gemcitabine for first-line treatment in unresectable or metastatic urothelial carcinoma.
The Food and Drug Administration (FDA) recently approved self-collection to test for HPV, the virus that causes cervical cancer. This gives women and people with…
Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell…
At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, James Harding, MD, discussed results from the EMERALD-1 study which demonstrated that…
Gaps in Transition From Pediatric to Adult Care for Individuals Living with Sickle Cell Disease Associated with More Hospital Visits
Data from the phase 3 INAVO120 trial support the priority review granted by the FDA to inavolisib, palbociclib, and fulvestrant for the treatment of PIK3CA-mutated…